GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

Benlysta (belimumab) Analytical Perspective • In-depth Benlysta (belimumab) Market Assessment This report provides a detailed market assessment of Benlysta (belimumab) in Seven Major Markets, i ...

Adding a single cycle of rituximab to belimumab (Benlysta) did not improve disease control for patients with systemic lupus erythematosus (SLE) in comparison with belimumab alone in a phase 3 ...

A patient receiving belimumab had a 3.5% annual probability of organ damage progression compared with an 8.7% annual probability of progression in the patients receiving standard of care alone.

A 2-year randomized controlled trial has found that belimumab plus standard therapy is superior to standard therapy alone in patients with lupus nephritis, according to data published in the New ...

Belimumab demonstrates notable efficacy for enhancing treatment outcomes among adults with active systemic lupus erythematosus (SLE) when added to standard therapy, according to study results ...

In older adults (ages 65+) with lupus, belimumab (Benlysta®) is a safe and effective treatment option, and is beneficial in overall populations with the disease. Belimumab was the first FDA-approved ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific ...

A new study finds that belimumab (Benlysta®) is an effective therapy option for people with cutaneous lupus erythematosus (CLE), a form of lupus that affects the skin. This study highlights that ...

When to Use Belimumab Where I do see this drug being used is in those patients with moderately severe disease, with symptoms such as more severe arthritis, serositis, fever, fatigue, and skin rash.

Joan T Merrill, MD, from the Oklahoma Medical Research Foundation in Oklahoma City, and colleagues evaluated the long-term safety profile of belimumab for SLE. Patients were randomized to receive ...